Molecular and histopathology directed therapy for advanced bladder cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular and histopathology directed therapy for advanced bladder cancer
Authors
Keywords
-
Journal
Nature Reviews Urology
Volume 16, Issue 8, Pages 465-483
Publisher
Springer Science and Business Media LLC
Online
2019-07-09
DOI
10.1038/s41585-019-0208-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular Profiling In Muscle Invasive Bladder Cancer: More Than The Sum Of Its Parts
- (2019) Gottfrid Sjödahl et al. JOURNAL OF PATHOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.
- (2018) Gregory Russell Pond et al. JOURNAL OF CLINICAL ONCOLOGY
- Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.
- (2018) Yohann Loriot et al. JOURNAL OF CLINICAL ONCOLOGY
- Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
- (2018) Min Yuen Teo et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- (2018) Thomas Powles et al. LANCET
- Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
- (2018) Manish R Patel et al. LANCET ONCOLOGY
- A practical guide to bladder cancer pathology
- (2018) Eva Compérat et al. Nature Reviews Urology
- Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma
- (2018) Tom Powles et al. Nature Reviews Urology
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base
- (2018) Trevor J. Royce et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Companies Scaling Back IDO1 Inhibitor Trials
- (2018) Cancer Discovery
- Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells
- (2018) Krishna Kalyan Kolluri et al. eLife
- Immune checkpoint inhibitors in small cell lung cancer
- (2018) Suchita Pakkala et al. Journal of Thoracic Disease
- Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer
- (2018) Daniel P. Petrylak et al. JAMA Oncology
- Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.
- (2018) Julius Strauss et al. JOURNAL OF CLINICAL ONCOLOGY
- EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.
- (2018) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
- (2018) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
- (2018) Yien Ning Sophia Wong et al. JOURNAL OF EXPERIMENTAL MEDICINE
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- EMA and FDA prune the checkpoint inhibitor treatment landscape
- (2018) Min Yuen Teo et al. Nature Reviews Urology
- Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder
- (2018) Shaheen Alanee et al. WORLD JOURNAL OF UROLOGY
- Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer
- (2018) Charles C. Peyton et al. JAMA Oncology
- Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
- (2018) Andrea Necchi et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
- (2017) Roland Seiler et al. EUROPEAN UROLOGY
- Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset
- (2017) Woonyoung Choi et al. EUROPEAN UROLOGY
- Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer
- (2017) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers to reveal discordant genomic and transcriptomic events and unique therapeutic opportunities.
- (2017) Daniel H. Hovelson et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
- (2017) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
- (2017) Daniel P Petrylak et al. LANCET
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
- (2017) Beatrice Seddon et al. LANCET ONCOLOGY
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
- (2017) Elizabeth R Plimack et al. LANCET ONCOLOGY
- Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
- (2017) Padmanee Sharma et al. LANCET ONCOLOGY
- Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma
- (2017) Somak Roy et al. MODERN PATHOLOGY
- Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
- (2017) Kenneth M. Felsenstein et al. Nature Reviews Urology
- Characteristics and clinical significance of histological variants of bladder cancer
- (2017) Marco Moschini et al. Nature Reviews Urology
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- A molecular and preclinical comparison of the PD-1–targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
- (2017) Petros Fessas et al. SEMINARS IN ONCOLOGY
- Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
- (2017) Shuguang Tan et al. Protein & Cell
- Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
- (2017) Thomas Powles et al. JAMA Oncology
- Squamous Cell Cancers: A Unified Perspective on Biology and Genetics
- (2016) G. Paolo Dotto et al. CANCER CELL
- Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
- (2016) P. M. Challita-Eid et al. CANCER RESEARCH
- Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA
- (2016) Fiona S Togneri et al. EUROPEAN JOURNAL OF HUMAN GENETICS
- Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer
- (2016) Charles Chuanhai Guo et al. EUROPEAN UROLOGY
- Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition
- (2016) Ana Collazo-Lorduy et al. EUROPEAN UROLOGY
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours
- (2016) Peter A. Humphrey et al. EUROPEAN UROLOGY
- Clear Cell Urothelial Carcinoma
- (2016) Kien T. Mai et al. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
- Primary sarcoma and sarcomatoid carcinoma of the urinary bladder: Comparison of clinical features, treatment, and survival.
- (2016) Jue Wang JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Synthetic Lethal Targeting of ARID1A -Mutant Ovarian Clear Cell Tumors with Dasatinib
- (2016) Rowan E. Miller et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms and regulation of endothelial VEGF receptor signalling
- (2016) Michael Simons et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Clinical, prognostic, and therapeutic aspects of urachal carcinoma—A comprehensive review with meta-analysis of 1,010 cases
- (2016) Tibor Szarvas et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use
- (2016) Vipulkumar Dadhania et al. EBioMedicine
- Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy
- (2015) Andrea Necchi et al. Clinical Genitourinary Cancer
- Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
- (2015) Elizabeth R. Plimack et al. EUROPEAN UROLOGY
- Nonurothelial Bladder Cancer and Rare Variant Histologies
- (2015) Daniel Willis et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers
- (2015) Kin Chan et al. NATURE GENETICS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
- (2014) Matthew I. Milowsky et al. EUROPEAN JOURNAL OF CANCER
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
- (2014) Ian Judson et al. LANCET ONCOLOGY
- Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer
- (2014) Mahul B Amin et al. MODERN PATHOLOGY
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes
- (2014) Mark D M Leiserson et al. NATURE GENETICS
- Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies
- (2014) Mark Linch et al. Nature Reviews Clinical Oncology
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
- (2014) J. S. Damrauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Plasmacytoid Bladder Cancer: Variant Histology With Aggressive Behavior and a New Mode of Invasion Along Fascial Planes
- (2014) Hristos Z. Kaimakliotis et al. UROLOGY
- Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes
- (2014) Anne Biton et al. Cell Reports
- Toward a Molecular Pathologic Classification of Urothelial Carcinoma
- (2013) Gottfrid Sjödahl et al. AMERICAN JOURNAL OF PATHOLOGY
- Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer
- (2013) Joshua J. Meeks et al. BJU INTERNATIONAL
- Phase II study of everolimus in metastatic urothelial cancer
- (2013) Matthew I. Milowsky et al. BJU INTERNATIONAL
- A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma
- (2013) Gregory R. Pond et al. BJU INTERNATIONAL
- Genomics-Driven Oncology: Framework for an Emerging Paradigm
- (2013) Levi A. Garraway JOURNAL OF CLINICAL ONCOLOGY
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
- (2013) Nienke van Rooij et al. JOURNAL OF CLINICAL ONCOLOGY
- Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
- (2013) Gopa Iyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
- (2013) Steven A Roberts et al. NATURE GENETICS
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
- (2013) Paul F Robbins et al. NATURE MEDICINE
- Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
- (2012) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Plasmacytoid Urothelial Carcinoma, a Chemosensitive Cancer with Poor Prognosis, and Peritoneal Carcinomatosis
- (2012) Farshid Dayyani et al. JOURNAL OF UROLOGY
- Targeting the TGFβ signalling pathway in disease
- (2012) Rosemary J. Akhurst et al. NATURE REVIEWS DRUG DISCOVERY
- Urachal Adenocarcinoma: A Clinician's Guide for Treatment
- (2012) Arlene Siefker-Radtke SEMINARS IN ONCOLOGY
- Fibroblast growth factor receptor-3 in urothelial tumorigenesis
- (2012) Gopa Iyer et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis
- (2011) Firas Abdollah et al. BJU INTERNATIONAL
- A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder
- (2011) Eugene J. Koay et al. CANCER
- Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer
- (2011) Robert Rosenblatt et al. EUROPEAN UROLOGY
- Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series
- (2011) Maria Rosaria Raspollini et al. HUMAN PATHOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer
- (2010) Jose J. Mansure et al. CANCER BIOLOGY & THERAPY
- Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study
- (2010) Matthew A. Powell et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers
- (2010) R. S. van der Post et al. JOURNAL OF MEDICAL GENETICS
- Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
- (2010) Guru Sonpavde et al. LANCET ONCOLOGY
- Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases
- (2010) Eva Compérat et al. PATHOLOGY
- Urachal Carcinoma
- (2009) Anuradha Gopalan et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
- (2009) Christian Wülfing et al. CANCER
- Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986
- (2009) Maria De Santis et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
- (2009) Joaquim Bellmunt et al. JOURNAL OF CLINICAL ONCOLOGY
- Adenocarcinoma Versus Urothelial Carcinoma of the Urinary Bladder: Comparison Between Pathologic Stage at Radical Cystectomy and Cancer-specific Mortality
- (2009) Giovanni Lughezzani et al. UROLOGY
- FGFR3 Mutations Indicate Better Survival in Invasive Upper Urinary Tract and Bladder Tumours
- (2008) Johanna M.M. van Oers et al. EUROPEAN UROLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies: Figure 1.
- (2008) Jorge A. Garcia et al. MOLECULAR CANCER THERAPEUTICS
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started